Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors

NCT04750954 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

29

Enrollment

NIH

Sponsor class

Conditions

Neuroendocrine Neoplasm

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Lutetium Lu 177 Dotatate
PROCEDURE: Magnetic Resonance Imaging
DRUG: Peposertib

Sponsor

National Cancer Institute (NCI)